How has been the historical performance of Biogen Pharma?

Answer:The historical performance of Biogen Pharma shows a fluctuating trend in its financial metrics over the years.

Breakdown:
Biogen Pharma's net sales have been inconsistent, with figures of 2.47 Cr in March 2022, 1.62 Cr in March 2021, and 0.95 Cr in March 2019, but dropping to 0.00 Cr in the subsequent years of March 2023, March 2024, and March 2025. Other operating income has varied, peaking at 2.38 Cr in March 2024 and showing a loss of -0.31 Cr in March 2022. Total operating income reached a high of 2.16 Cr in March 2022 but fell to 0.84 Cr by March 2025. The total expenditure, excluding depreciation, peaked at 2.18 Cr in March 2022 before declining to 1.13 Cr in March 2025. Operating profit, excluding other income, was negative in March 2025 at -0.29 Cr, contrasting with a profit of 1.93 Cr in March 2024. The profit before tax mirrored this trend, showing a loss of -0.29 Cr in March 2025 after a profit of 1.93 Cr in March 2024. The net profit also reflected this decline, with a loss of -0.29 Cr in March 2025 compared to a profit of 1.93 Cr in March 2024. The company's total assets increased to 56.82 Cr in March 2024 from 54.83 Cr in March 2023, while total liabilities were 56.82 Cr in March 2024, indicating a balance sheet that reflects the company's financial struggles. Cash flow from operating activities remained stable at 1.00 Cr in both March 2024 and March 2023, but cash flow from investing activities showed a negative trend, indicating increased outflows. Overall, Biogen Pharma's financial performance has been marked by significant volatility, particularly in profitability and sales.